Business
Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million
This strategic acquisition positions Pearsanta for robust growth: expanding opportunities in women’s health, spanning endometriosis to ovarian cancer, and in
About this update from Aditxt, Inc.
[{"type":"text","content":"\nThis strategic acquisition positions Pearsanta for robust growth: expanding opportunities in women’s health, spanning endometriosis to ovarian cancer, and in men’s health starting with prostate cancer\n\n\n RICHMOND, Va.--(BUSINESS WIRE)--\nAditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announces that the Company and its subsidiary, Pearsanta, Inc. (“Pearsanta”), has acquired MDNA Life Sciences Inc.’s (“MDNA”) proprietary, early disease and cancer detection platform. This strategic move reinforces Pearsanta’s dedication to enhancing patient outcomes through early disease detection and the power of precision diagnostics. The portfolio of assets to be acquired includes the pioneering Mitomic™ technology that harnesses the unique attributes of Mitochondrial DNA (“mtDNA”) to detect diseases at their earliest stages with precision and minimal invasiveness.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240108557137/en/\nEmpowering Precision Medicine: Pearsanta’s Expansion\n\n\nMDNA’s Mitomic™ technology provides a tool for identifying biomarkers associated with various diseases that lead to mtDNA mutations. The platform includes a rich biomarker portfolio addressing a wide range of high-priority health concerns beyond oncology, extending into areas of substantial medical need. The technology has uncovered promising biomarkers and generated an extensive in-silico database through advanced computer simulations. Highlights from the asset portfolio include:\n\n\n\nThe Mitomic Endometriosis Test (MET™) is in development as a blood-based assay for diagnosis of endometriosis. This test aims to provide early diagnostic insights, potentially reducing delays in diagnosing endometriosis.\n\n\n\nThe Mitomic Prostate Test (MPT™) is currently under development as a blood-based assay for diagnosis of prostate cancer. We believe that this test holds the potential to provide more specific and clinically informative data especially in the prostate-specific antigen (PSA) grey zone. It aims to address the challenges of over-diagnosis and mitigate risks associated with low-grade cancers.\n\n\n\nAn extensive development pipeline including tests for various cancers such as ovarian, lu...